Leap Therapeutics Inc is a biopharmaceutical company. The company is acquiring and developing novel therapeutics at the leading edge of cancer biology. Its programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body's immune system to identify and attack cancer. Leap has two clinical stage programs: DKN-01 and TRX518. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1, or DKK1, a protein that regulates important cell signaling pathways, known as the Wnt pathways. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR, a receptor found on the surface of a wide range of immune cells.